Welcome to Dwaey, specifically on Teicoplanin page.
This medicine contains important and useful components, as it consists of
Teicoplanin is available in the market in concentration.
Teicoplanin
Before initiating Teicoplanin therapy, patients should consult their healthcare provider. Key precautions include:
- Allergic Reactions: Some patients may develop hypersensitivity reactions to Teicoplanin, such as rash, itching, or more severe anaphylactic reactions. Those with a known allergy to vancomycin or other glycopeptide antibiotics should avoid using Teicoplanin.
- Renal Impairment: Teicoplanin is primarily eliminated via the kidneys, so it must be used with caution in patients with renal impairment. Dosage adjustments may be required in individuals with impaired kidney function to avoid drug accumulation and potential toxicity.
- Hearing Impairment: Teicoplanin is a glycopeptide antibiotic, and while it has a lower incidence of ototoxicity than vancomycin, caution should be exercised in patients with existing hearing issues or those undergoing concurrent ototoxic drug therapy.
- Pregnancy and Breastfeeding: Teicoplanin is categorized as Category C during pregnancy, meaning it should be used only if the potential benefits outweigh the risks. It is not known whether Teicoplanin is excreted in breast milk, so a healthcare provider's guidance is necessary for breastfeeding mothers.
- Elderly Patients: Caution is advised in elderly patients, as they may have age-related renal function decline, which can affect the clearance of Teicoplanin from the body.
Teicoplanin is indicated for the treatment of serious infections caused by Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus (MRSA). Its indications include:
- Bone and Joint Infections: Teicoplanin is used to treat osteomyelitis and infected joints caused by susceptible Gram-positive organisms, including Staphylococcus aureus.
- Endocarditis: It is indicated for bacterial endocarditis caused by Staphylococcus aureus and other Gram-positive cocci.
- Skin and Soft Tissue Infections: Effective against cellulitis, abscesses, and other skin infections caused by Staphylococcus aureus or Streptococcus pyogenes.
- Respiratory Infections: Teicoplanin is used for treating severe pneumonia and other respiratory tract infections caused by Gram-positive bacteria.
- Bloodstream Infections: It is also used in the management of bacteremia and sepsis due to resistant Gram-positive bacteria.
- Prophylaxis in High-Risk Surgeries: Teicoplanin is occasionally used as a prophylactic antibiotic in surgeries with a high risk of Gram-positive infections, such as cardiothoracic surgeries.
Teicoplanin should not be used in the following situations:
- Hypersensitivity: It is contraindicated in patients with a known hypersensitivity to Teicoplanin or any components of the formulation. This includes those who are allergic to other glycopeptide antibiotics, such as vancomycin.
- Severe Renal Impairment: Teicoplanin is contraindicated in patients with severe renal dysfunction, particularly those with creatinine clearance below 30 mL/min, unless specifically adjusted by a healthcare provider.
- Pregnancy (First Trimester): While Teicoplanin can be used during pregnancy under a healthcare provider's supervision, its use during the first trimester is generally avoided unless absolutely necessary due to the limited safety data available.
Common and serious side effects of Teicoplanin include:
- Injection Site Reactions: Pain, redness, or swelling at the injection site is a common adverse effect, especially with intravenous administration.
- Rash: Skin rash may occur as a sign of an allergic reaction. In severe cases, Stevens-Johnson syndrome or toxic epidermal necrolysis may occur, requiring immediate medical attention.
- Nephrotoxicity: Though less common than vancomycin, Teicoplanin can still cause renal toxicity in susceptible individuals, especially in those with pre-existing renal conditions. Renal function should be regularly monitored during treatment.
- Ototoxicity: High doses or prolonged use of Teicoplanin can cause hearing loss or tinnitus, particularly in patients receiving concomitant ototoxic drugs.
- Gastrointestinal Distress: Some patients may experience nausea, vomiting, or diarrhea during treatment.
- Thrombocytopenia: Rarely, Teicoplanin may cause low platelet counts, leading to an increased risk of bleeding.
- Fever and Chills: Some individuals may experience flu-like symptoms such as fever, chills, or shivering, particularly at the start of therapy.
2
Teicoplanin is a glycopeptide antibiotic that exerts its effect by:
- Inhibiting Cell Wall Synthesis: Teicoplanin binds to the D-alanyl-D-alanine portion of bacterial cell wall precursors. This inhibits the synthesis of peptidoglycan, a critical component of the bacterial cell wall.
- Bactericidal Activity: By inhibiting cell wall synthesis, Teicoplanin causes bacterial cell lysis, resulting in a bactericidal (bacteria-killing) effect.
- Targeting Gram-Positive Organisms: It is effective primarily against Gram-positive bacteria, including MRSA, Streptococcus, and Enterococcus species. It does not affect Gram-negative bacteria due to its large molecular size and inability to penetrate their outer membrane.
- Resistance Prevention: Teicoplanin is more effective than vancomycin in some cases, as it may overcome certain types of vancomycin-resistant enterococci (VRE).
Teicoplanin may interact with other medications, leading to increased risks of side effects or reduced efficacy:
- Nephrotoxic Drugs: When used in combination with other nephrotoxic drugs, such as aminoglycosides (e.g., gentamicin, amikacin) or nonsteroidal anti-inflammatory drugs (NSAIDs), there is an increased risk of kidney damage. Close monitoring of renal function is recommended in such cases.
- Ototoxic Drugs: Concurrent use with ototoxic medications (e.g., loop diuretics like furosemide) should be approached with caution due to the potential for hearing damage.
- Warfarin: Teicoplanin may interact with warfarin, affecting the prothrombin time. Frequent monitoring of the international normalized ratio (INR) is required in patients on warfarin therapy to prevent bleeding complications.
- Probenecid: The use of probenecid, a drug that inhibits renal excretion, may lead to increased blood levels of Teicoplanin, increasing the risk of adverse effects.
The recommended adult dose of Teicoplanin varies depending on the condition being treated:
- For Severe Infections (e.g., endocarditis, osteomyelitis): The initial dose is typically 400 mg intravenously once daily for the first 3 days. Following this, a maintenance dose of 200 mg to 400 mg daily is used.
- For Skin and Soft Tissue Infections: The initial dose is usually 200 mg to 400 mg intravenously once a day, followed by 200 mg daily as a maintenance dose.
- For Prophylaxis in surgery, a single dose of 400 mg is administered before the procedure.
- The duration of therapy is dependent on the type and severity of the infection and may range from 7 to 14 days.
The dosage of Teicoplanin for children is typically based on their weight:
- For children, the dose is generally 6 mg/kg of body weight, administered once daily for the first 3 days. After this initial period, the dose may be reduced
to 3–6 mg/kg daily, depending on the clinical response and severity of the infection.
---
Teicoplanin is a potent glycopeptide antibiotic used to treat serious Gram-positive infections, especially MRSA. While it is generally well-tolerated, it requires careful monitoring for potential renal toxicity, ototoxicity, and allergic reactions. Adjustments in dosing are necessary in patients with renal impairment or those receiving nephrotoxic and ototoxic medications.
For patients with renal impairment, the dose of Teicoplanin should be adjusted:
- Mild Renal Impairment (CrCl > 50 mL/min): Standard dosing can be used.
- Moderate Renal Impairment (CrCl 30–50 mL/min): A reduced dose of 200 mg per day should be considered, with monitoring of renal function.
- Severe Renal Impairment (CrCl < 30 mL/min): In cases of severe renal impairment, the dosing schedule may need to be modified, and closer monitoring of renal function is required.
Not available in a medicine form yet